Lantern Pharma announced it will host an investor, analyst and shareholder briefing on April 9, 2026, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform's capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern's growth roadmap.
The demonstration matters because it showcases a potentially transformative approach to oncology drug development. Lantern Pharma is an AI-driven company that aims to transform the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development.
The importance of this event lies in the demonstrated efficiency gains. According to the company, its newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–2.5 million per program. This represents a significant acceleration compared to traditional drug development timelines and costs, which can take over a decade and cost billions of dollars.
The impact extends to Lantern's growing pipeline. The company has accelerated the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate program. The company's lead development programs include a Phase 2 clinical program and multiple planned Phase 1b/2a clinical trials. Lantern has also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of therapies for CNS and brain cancers.
The market potential underscores the significance of this technology demonstration. Lantern's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD. The rare cancer market opportunity represents a substantial area of unmet medical need where AI-driven approaches could potentially deliver new treatments more efficiently.
Investors and analysts can access additional information through the company's newsroom at https://ibn.fm/LTRN. The briefing will feature participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia, who will provide insights into the platform's capabilities and the company's strategic direction. The demonstration of withZeta.ai represents a key milestone in showcasing how artificial intelligence can be applied to complex biomedical challenges in oncology.
